

SpineGuard publishes robotic patent application for use of its DSG real-time sensing technology to guide surgical robots

PARIS and SAN FRANCISCO, April 30, 2019 – 08h00 CEST – SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG® real time digital technology for surgical guidance intended to secure and streamline skeletal implant placement, announced today the publication of a patent application for using its DSG sensing technology to provide real time in-situ feedback to robotic surgical guidance platforms.

The measurement of the electrical conductivity of tissues is used to prevent breaches through the bone cortex that if not detected could create dramatic surgical complications. A patent application was filed in France in October 2017 and is now being extended internationally via the PCT (Patent Cooperation Treaty) procedure. The patent describes means to implement the DSG sensing technology to guide and enhance the safety of surgical assistance robotic platforms and is the result of the collaboration between SpineGuard and ISIR (Institut des Systèmes Intelligents et de Robotique). The joined applicants are SpineGuard, Université Pierre et Marie Curie (now Sorbonne University), INSERM (Institut National de la Santé et de la Recherche Médicale) and CNRS (Centre National de la Recherche Scientifique).

Stéphane Bette, CEO and co-founder of SpineGuard, said: *“We are thrilled by the ongoing development using DSG technology to feed robots with meaningful real-time in-situ information from the tissues that no one else can provide and is radiation-free. This first patent application in robotics is the first step in the development of continuous innovations in robotics from our collaboration with the ISIR lab of Sorbonne University. IP is a crucial component of the enterprise value of SpineGuard and a key asset in our search for industry partners to implement the technology adapted to their vision and platforms.”*

Guillaume Morel, Professor at the Sorbonne University, adds: *« It is critical that our partners can create value from the results of our collaborative efforts. That is why we contractually offered to SpineGuard to purchase the exclusive rights of exploitation in their application field for this shared IP. SpineGuard was thereby granted the assurance of the creation of valuable assets, and financial visibility, as soon as our agreement was signed. That is the basis of a serene and secured collaboration. On the technology front, this patent application is a significant first step, it entails the general principle of coupling the robotic guidance with the DSG measurement. The satisfying results we obtained very quickly enabled us to file for this first patent application and ongoing developments confirm the promises. I am confident that other patents will follow to allow SpineGuard to deploy its technology in a broader context of surgical gesture assistance by numerical and robotic means.”*

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary real-time digital technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 70,000 surgical procedures worldwide. Fourteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard

Stéphane Bette
Chief Executive Officer
Tel: +33 (0) 1 45 18 45 19
s.bette@spineguard.com

Manuel Lanfossi
Chief Financial Officer
Tel: +33 (0)1 45 18 45 19
m.lanfossi@spineguard.com

NewCap

Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel: +33 (0)1 44 71 94 94
spineguard@newcap.eu

